SNY241220C47500
- 1.60
- -0.30-15.79%
Sanofi Newsroom
FDA Accepts SNY and REGN's Dupixent Re-Submitted SBLA for Urticaria
Sanofi's Sarclisa Nears EU Approval for Myeloma
Express News | Us CDC Says Since April Confirmed Avian Influenza A(H5) Virus Infections In 52 People In US; Aware Of Human Case Of H5N1 Bird Flu Reported In Canada & Is In Communication With Public Health Agency Of Canada
US Manufacturing Index Rises To 43, Highest Since 2020
PFE, Moderna Shares Fall As Trump's RFK Pick Weighs on Vaccine Makers
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
RFK Jr. News Hits Global Pharma Stocks -- WSJ
Vaccine Sector Sell-Off Looks Overdone -- Market Talk
Stocks to Watch Friday: Tesla, Domino's, Palantir, Ulta -- WSJ
Sanofi, Regeneron's Dupixent SBLA Accepted For FDA Review To Treat Chronic Spontaneous Urticaria
US FDA Accepts Revised Application for Sanofi's Inflammatory Skin Disease Drug
Express News | Sanofi - Resubmission Includes New Pivotal Data Which Confirm Dupixent Significantly Reduced Itch and Hive Activity
Communiqué De Presse - Sanofi Renforce La Bioproduction D'anticorps En France Avec Un Investissement De Plus De 40 Millions D'euros Sur Son Site De Lyon Gerland
Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom
Vaccines Makers Close Lower on Reports RFK Jr May Head HHS
Express News | Viking Global Investors LP Dissolves Share Stake in Sanofi
Sarclisa Recommended For EU Approval By The CHMP To Treat Transplant-Ineligible Newly Diagnosed Multiple Myeloma; Sarclisa Recommended For EU Approval By CHMP; Sarclisa Could Be First Anti-CD38 Therapy In EU For NDMM
Neuraxpharm Reports Another Year of Sustained Growth and International Expansion
Press Release: Sarclisa Recommended for EU Approval by the CHMP to Treat Transplant-ineligible Newly Diagnosed Multiple Myeloma
Humanitarian Organization Criticizes Eli Lilly, Novo Nordisk And Sanofi Of Having 'Double Standards' For High Insulin Price